{"links":{"html":"https://www.erudio.com/reports/be6a-lung-01-nct06012435","json":"https://www.erudio.com/reports/be6a-lung-01-nct06012435.json","markdown":"https://www.erudio.com/reports/be6a-lung-01-nct06012435.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"be6a-lung-01-06012435"}},"request":"https://www.erudio.com/contact?report=be6a-lung-01-06012435"},"offer":{"cited_commentary_sources":9,"verified_hcp_statements":33,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":7,"optional":true,"price_per_verified_person_usd":15,"price_usd":105,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"be6a-lung-01-nct06012435"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=be6a-lung-01-06012435","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/be6a-lung-01-nct06012435","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T08:13:25.380553Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":0},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":2,"title":"Secondary endpoints"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":2,"title":"IB6 biology, testing burden and predictive uncertainty"},{"claim_count":6,"coverage":"discussed","id":"A2","source_count":2,"title":"Mechanistic rationale and investigational checkpoint combinations"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":1,"title":"Unmet need and the conditional threshold for second-line adoption"},{"claim_count":7,"coverage":"discussed","id":"A4","source_count":5,"title":"ADC failure mechanisms and limits of cross-disease extrapolation"}],"counts":{"cited_sources":9,"claims_by_expression_type":{"comparison":3,"experience":1,"interpretation":7,"opinion":11,"question":1,"restatement":9,"unspecified":1},"claims_by_kind":{"attributed_opinion":7,"source_observation":26},"clinician_statements":7,"evidence_units":24,"findings":6,"organisational_accounts":2,"people_cited":9,"people_identity_verified":7,"people_total":9,"screened_sources":27,"verified_claims":33},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":4,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":9},"ma_question":true,"named_voices":6,"passages":7,"sources":7,"sources_by_kind":{"commentary":7}},"title":"Post-result reactions extend from disappointment with the drug to concern about ADC development in NSCLC"},{"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":2},"has_counterview":true,"limitations":2,"links":{"context":0,"support":5},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Subgroup optimism remains exploratory rather than an established second-line benefit"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":0,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":4,"passages":6,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Docetaxel is viewed as inadequate yet more difficult to surpass than expected"},{"id":"F4","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":4},"has_counterview":true,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"High IB6 expression supports a low-testing-burden argument, but does not establish predictive selection"},{"id":"F5","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":5},"has_counterview":true,"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":2,"passages":6,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"The anticipated practice change was explicitly conditional, while confidence in the design was unusually strong"},{"id":"F6","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":4},"has_counterview":false,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":6,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Combination interest rests on a biological hypothesis rather than demonstrated rescue of the negative comparison"}],"medical_affairs_question":"What evidence would distinguish a clinically meaningful second-line opportunity from exploratory trends, and establish whether IB6 testing or a combination strategy improves that decision?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Negative OS reactions also challenge ADC expectations"},{"id":"section-2","level":2,"title":"Subgroup signals are a research opening, not a positive primary result"},{"id":"section-3","level":2,"title":"Docetaxel remains an unsatisfactory but meaningful hurdle"},{"id":"section-4","level":2,"title":"High expression and predictive value are different arguments"},{"id":"section-5","level":2,"title":"Conditional adoption should not be confused with an observed practice change"},{"id":"section-6","level":2,"title":"Combination development remains a hypothesis to test"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":3}],"id":"T1","label":"Primary endpoint: Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":5}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F5","shared_claims":3}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F5","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T08:13:25.380553Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T08:34:35Z","record_hash":"aa47ad1c3043871d3a84bef18b613bd9a0cc03bd087afa5d66b24184a994622f","release_hash":"8bd1d69a59a21ea1f4998622459f282fe74273565d6c9aedc43608cba16cdb89","report_id":"erudio-nct06012435","run_id":"fd3aa3dd-dbf7-4836-acb1-b93666505066","schema_version":"5.0","slug":"be6a-lung-01-06012435","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"BE6A LUNG-01 asks whether sigvotatug vedotin improves survival over docetaxel in previously treated non-small-cell lung cancer. Commentary in the sources reviewed for this edition framed anticipated changes in second-line practice as conditional. Podcast enthusiasm for treatment change and confidence in the design contrast with clinician concern about ADC development. Subgroup optimism remains exploratory, and whether subgroup findings or combination strategies can establish a role for sigvotatug vedotin remains open.","meta_description":"27 sources screened · 33 verified statements (7 from clinicians verified by NPI or staff page) from 9 sources · 6 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-65ba5cebadcaa9ce72e8","claim-ee7c5feb5cf240ee5301"],"id":"F5","paraphrase":"A podcast discussion addressed what evidence would justify changing second-line treatment and how the trial’s statistical design should be assessed.","publication_caveats":["The podcast does not establish which individuals made these statements.","The sources reviewed for this edition did not include a full protocol or detailed statistical plan for assessing the discussion of statistical rigor."],"source_channel":"podcast","source_date":"2025-12-17","title":"The anticipated practice change was explicitly conditional, while confidence in the design was unusually strong"}]},"publication":{"approved_at":"2026-10-28T08:34:35Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":27},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","18 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are not representative of all HCP discussion. Source totals and reposts must not be interpreted as counts of independent clinical opinions.","Twenty-two potentially relevant sources without a direct trial name were not reviewed. One additional thread was unavailable and three passages were not fully assessed; unnamed or differently transcribed discussions may also be missing.","No protocol or exact-trial results publication was available in the sources reviewed, and no exact sigvotatug vedotin label was identified. The report cannot independently resolve detailed eligibility, statistical methods or benefit-risk conclusions.","The podcast does not establish which named individual delivered each statement. Its views remain attributed to unidentified speakers.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The December 2025 discussion and June/October 2026 posts concern different sources and settings. Their dates do not establish a readout or session date, a change of mind, or a direct disagreement between speakers."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":9},"count":9,"evidence_window":{"end":"2026-10-26","start":"2025-12-17"},"retrieval_snapshot":"2026-10-28T07:55:31.664442Z","timeline":[{"count":1,"week":"2025-W51"},{"count":4,"week":"2026-W26"},{"count":3,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06012435:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06012435:context","quote_policy":"short_quote_link_out"},{"id":"openfda:2992d633-08fa-44f3-b14d-41700f24686b:20260415","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3lwcl46kzf22m","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d2207e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1760842358302929333:e53bfd7b-4eaf-4a44-be05-04c112d31835","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1875287209781436461:e43f2464-47fd-41a7-9875-20be863144f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1970239176307036560:d1eadd38-05f5-4728-954a-53d62e83e6cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009477372949811645:612b663c-029b-487a-8d0e-f172ab8e561a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069156973354909906:bd300ad4-6159-45e2-a319-8fc23753a6ba","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069157645336891887:354dcbcf-1a3e-4ddf-a2d3-c95a85ab5dc2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069175544554668492:64eca27a-0370-4055-a021-8e2dbee39b83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069211585105535394:4f02d4ef-fb30-4dc8-a581-6fcf6a190885","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069373502298132895:15dcafb9-6691-4c55-b416-b356f44f13c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069404988049125716:50de51c1-cf5d-442e-b50c-510c4a0d0abe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069438098757366032:270e543f-7c51-4160-8c3c-daffb6b00115","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069467139313197507:3260db28-40f8-4c19-827f-49e7dbaa9071","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069555486832337354:dd56cc93-7d96-466e-a3ff-5e6ef0595103","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2069724211350847697:d7b9e46a-6678-4d22-aae7-532f99b7380b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102759897372962850:8a65040e-16e4-49ac-b082-0d1fd773ec10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104960069372666151:60040d34-b93b-400a-91d4-d2c2f5b0322a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110059311510569021:982593ec-db6d-4161-bf1f-a415e3218e64","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113310373298208931:eda3a8bf-789e-4f65-9132-7a1c1f61bfc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114207062293094519:0341560f-b5d5-42d1-8a7a-0d2867f7b04f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114301693131415714:e3d1356e-b56e-4065-947c-15a902b04ee4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114302395413057977:855f5948-6006-4c06-ac7b-e5792db365b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114303647924343255:d77fdadd-d9f4-45ab-a46b-130f237aa675","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114303781802266973:507d1a4c-8397-4c6e-89fd-b8511fbec0a9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114304895922700649:76f97758-45ed-43f2-86bc-6293b2d99c4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114546571081625898:afba8656-87fb-4610-aa32-4b1439125964","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":25,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":27},"count":27,"evidence_window":{"end":"2026-10-26","start":"2024-02-23"},"retrieval_snapshot":"2026-10-28T07:55:31.664442Z","timeline":[{"count":1,"week":"2024-W08"},{"count":1,"week":"2025-W01"},{"count":1,"week":"2025-W33"},{"count":1,"week":"2025-W39"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W02"},{"count":10,"week":"2026-W26"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W42"},{"count":7,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: sigvotatug vedotin","status":"unmapped"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)"],"brief_title":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":762,"type":"ACTUAL"},"interventions":[{"name":"sigvotatug vedotin","synonyms":["SGN-B6A; PF-08046047"],"type":"DRUG"},{"name":"docetaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06012435","official_title":"A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-05-18","type":"ACTUAL"},"primary_endpoints":[{"description":"The time from date of randomization to date of death due to any cause.","measure":"Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)","timeFrame":"Approximately 5 years"}],"registry_last_updated":"2026-07-23","registry_url":"https://clinicaltrials.gov/study/NCT06012435","short_name":"BE6A LUNG-01","short_name_basis":"registry_title","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","start_date":{"date":"2024-02-21","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"SGNB6A-002","type":"sponsor_study_id"},{"domain":"Alias Study Number","id":"C5751002","type":"other"},{"domain":"CTIS (EU)","id":"2023-503827-25-01","type":"registry"}],"study_type":"INTERVENTIONAL"}}}